Long-term Use of Mifepristone in the Treatment of Adenomyosis
NCT05151016 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 140
Last updated 2021-12-09
Summary
The design was a prospective, randomized, positive-control, parallel-group, multicenter clinical trial. The study included a randomized, parallel-group treatment for 24 weeks in 140 subjects from eight hospitals in seven cities across the country who were diagnosed with Adenomyosis and associated symptoms (dysmenorrhea, with or without heavy menstrual flow) , the subjects were randomly assigned to the following two groups:
1. Study Group: mifepristone tablets, 10 mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks;
2. Control Group: dafinil (Triptorelin Acetate) , 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
Conditions
- Adenomyosis
- Mifepristone
Interventions
- DRUG
-
Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks
- DRUG
-
Triptorelin Acetate
dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
Sponsors & Collaborators
-
Ningbo Women & Children's Hospital
collaborator OTHER -
Jiaxing Maternity and Child Health Care Hospital
collaborator OTHER -
The Affiliated Hospital of Medical School, Ningbo University
collaborator UNKNOWN -
Qilu Hospital of Shandong University
collaborator OTHER -
Obstetrics & Gynecology Hospital of Fudan University
collaborator OTHER -
The First Affiliated Hospital with Nanjing Medical University
collaborator OTHER -
Anhui Provincial Hospital
collaborator OTHER_GOV -
Women's Hospital School Of Medicine Zhejiang University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-01
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- China
Study Locations
More Related Trials
-
Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids
NCT00886873 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Missed Period Pill Study
NCT04940013 ·Status: TERMINATED ·Phase: PHASE4
-
The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates
NCT02449161 ·Status: TERMINATED ·Phase: PHASE3
-
Rectal Misoprostol in Women Undergoing Myomectomy for Intraoperative Blood Loss: A Randomized Placebo-controlled Study
NCT02908295 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea
NCT02614781 ·Status: COMPLETED
-
Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP)
NCT00957346 ·Status: TERMINATED ·Phase: PHASE3
-
Impact of Misoprostol on Blood Loss In Myomectomy Operations
NCT02061657 ·Status: COMPLETED ·Phase: PHASE3
-
A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas
NCT00219778 ·Status: TERMINATED ·Phase: PHASE2
-
Sublingual vs Vaginal Misoprostol for Termination of First Trimesteric Missed Abortion
NCT05001061 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Sublingual Misoprostol Versus No Cervical Priming Before Hysteroscopic Resection of Symptomatic Uterine Niches
NCT07271056 ·Status: COMPLETED ·Phase: NA
-
Medical Abortion for Emergency Contraception Failure
NCT00677755 ·Status: COMPLETED ·Phase: NA
-
Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
NCT01165307 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination
NCT00310921 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy.
NCT03509168 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy
NCT02716142 ·Status: COMPLETED ·Phase: PHASE4
-
Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion
NCT00994734 ·Status: COMPLETED ·Phase: NA
-
Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death
NCT02633761 ·Status: TERMINATED ·Phase: PHASE3
-
Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial
NCT00784186 ·Status: COMPLETED ·Phase: NA
-
Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers
NCT00832871 ·Status: TERMINATED ·Phase: NA
-
Misoprostol For Nulliparous Women Before Hysteroscopy
NCT01156948 ·Status: UNKNOWN ·Phase: PHASE3
-
Misoprostol for Non-Viable Pregnancies
NCT00426491 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage
NCT07109947 ·Status: RECRUITING ·Phase: NA
-
Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids
NCT00881140 ·Status: COMPLETED ·Phase: PHASE2
-
Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))
NCT00969982 ·Status: COMPLETED ·Phase: NA
-
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
NCT00483327 ·Status: COMPLETED ·Phase: PHASE2